论文部分内容阅读
[目的]探讨康复新液联合盐酸伊托必利治疗反流性食管炎(RE)的有效性和安全性。[方法]随机抽取2012年1月~2015年3月消化科门诊及住院的109例RE患者,并经内镜检查进一步明确诊断,随机分为治疗组和对照组,其中治疗组56例、对照组53例。治疗组给予康复新液加盐酸伊托必利治疗,对照组给予传统H2受体拮抗剂(雷尼替丁)+盐酸伊托必利治疗,疗程均为4周。比较2组的临床疗效,观察2组治疗前后的食管pH值变化等情况。[结果]治疗组总有效率为96.43%,高于对照组的81.13%,差异有统计学意义(P<0.05);治疗后2组患者的食管内pH均有所改善,且治疗组的改善程度明显优于对照组(P<0.05)。[结论]康复新液联合盐酸伊托必利治疗RE能更有效提高治疗效果,并且患者生活质量明显改善,康复新液治疗RE具有重要临床价值。
[Objective] To investigate the efficacy and safety of Kangfuxin combined with Itopride Hydrochloride in the treatment of reflux esophagitis (RE). [Methods] A total of 109 patients with RE in outpatients and inpatients from January 2012 to March 2015 were randomly selected and further confirmed by endoscopy. The patients were randomly divided into treatment group and control group, of which 56 patients in treatment group and control group Group of 53 cases. The treatment group was given Kangfuxin solution plus itopride hydrochloride, while the control group was given traditional H2 receptor antagonist (ranitidine) + itopride hydrochloride for 4 weeks. The clinical effects of two groups were compared and the change of esophageal pH before and after treatment was observed. [Results] The total effective rate of the treatment group was 96.43%, which was higher than that of the control group (81.13%), the difference was statistically significant (P <0.05); the esophageal pH was improved in both groups after treatment, and the treatment group improved The degree was significantly better than the control group (P <0.05). [Conclusion] Kangfuxin combined with Itopride Hydrochloride in the treatment of RE can improve the therapeutic effect more effectively and the quality of life of the patients improved obviously. Kangfuxinye has important clinical value in the treatment of RE.